New Cellectis video showcases allogeneic CAR-T tech

The race to develop the world's best CAR-T therapy for cancer has inspired some fancy marketing efforts on behalf of some of the leaders in the field. Case in point: France's Cellectis ($CLLS), which is developing an R&D hub in Manhattan, has unveiled a cool new 2-minute video which illustrates how it plans to use TALEN gene editing tech to create allogeneic, or off-the-shelf, engineered T cell treatments. Keep in mind, though, that while Cellectis' approach has helped inspire a big IPO for the company, the company is also quick to acknowledge that it's only been tried in animals so far. The first human study lies ahead.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.